Vertex Pharma (VRTX) Tops Q1 EPS by 14c; Reiterates Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
Go back to Vertex Pharma (VRTX) Tops Q1 EPS by 14c; Reiterates Outlook
April 26, 2018 4:05 PM EDT
-First-quarter 2018 total CF product revenues of $638 million, a 33%
increase compared to $481 million in the first quarter of 2017-
-Company reiterates full-year 2018 total CF product revenue guidance
of $2.65 to $2.80 billion and combined non-GAAP R&D and SG&A expense
guidance of $1.50 to $1.55 billion-
BOSTON--(BUSINESS WIRE)--
Vertex
Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported
consolidated financial results for the first quarter ended March 31,
2018 and reviewed recent progress with its approved and investigational
medicines. Vertex also reiterated its guidance for full-year 2018 total
CF product revenues and combined GAAP and non-GAAP R&D and SG&A expenses.
 ...
More
